Trial Profile
DAS181 for Severe COVID-19: Compassionate Use
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 May 2020
Price :
$35
*
At a glance
- Drugs Oplunofusp (Primary)
- Indications COVID 2019 infections
- Focus Expanded access; Therapeutic Use
- 01 May 2020 Status changed from recruiting to completed.
- 02 Apr 2020 According to an Ansun Biopharma Media Release, in the first 14 days, the first two patients no longer required supplemental oxygen, and showed stabilized vital signs, increased oxygen saturation, and resolution of infiltrates on chest CT scans. The third patient, who had been a persistent SARS-CoV-2 carrier for more than 33 days, was completely virus-free before the end of the 10-day DAS181 regimen and met all discharge criteria, and the fourth is currently undergoing treatment.
- 02 Apr 2020 According to an Ansun Biopharma Media Release, Dr. Ke Hu is the principal investigator.